Saimot AG, 2001-01: Review of benzimidazole chemotherapy for liver hydatidosis that puts numbers on the toxicity seen at treatment doses: transaminase rises in about 10-20% of patients, self-limited and reversible, with severe pancytopenia or agranulocytosis described as exceptional.
About 10% to 20% of patients develop self-limited, reversible rises in transaminase levels; clinically severe pancytopenia or agranulocytosis is exceptional.
Saimot AG, 2001-01: Review of benzimidazole chemotherapy for liver hydatidosis that puts numbers on the toxicity seen at treatment doses: transaminase rises in about 10-20% of patients, self-limited and reversible, with severe pancytopenia or agranulocytosis described as exceptional.
